

## IN THE SPECIFICATION:

**The paragraph bridging pages 2 and 3, please replace with the following new paragraph:**

Interfering in the organism, for instance when taking a tissue sample, strains the organism in most of the cases and often requires a great number of instruments and involves risks to the health. Thus, non-invasive techniques are preferred since it is comparatively easy to take samples of the above-mentioned body fluids and excretions. Furthermore, as not every host reacts in the same way to a certain pathogen or parasite and as the host's reaction is delayed and may also persist after the pathogen [[of]] or parasite has been removed from the organism, direct methods should always be preferred. Ideally, a diagnosis is made by means of the non-invasive, direct detection of the pathogen or parasite in body fluids or excretions.

Page 16, paragraph 1, please replace with the following paragraph:

In another particularly preferred embodiment, the heavy chain of the antibody binding an Hsp60-epitope has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the following CDRs.

CDR1: GFSLSRYSVH (SEQ ID NO:1)  
CDR2: MIWGGGSTDYNSGLKS (SEQ ID NO:2)  
CDR3: NMGGGRYPDYFDY (SEQ ID NO:3)

Page 16, paragraph 2, please replace with the following paragraph:

In another particularly preferred embodiment, the DNA sequence encoding the heavy chain of the antibody binding an Hsp60-epitope has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the following CDRs:

CDR1: GG GTTCTCTCATTA TCCAGATATA GTGTACAC (SEQ ID NO:4)  
CDR2: ATGATATGGG GTGGTGGAAG CACAGACTAT AATTCAAGTC  
          TCAAATCC (SEQ ID NO:5)  
CDR3: AATATG GGGGGTAGGT ACCCGGACTA CTTTGACTAC  
          (SEQ ID NO:6)

Page 16, paragraph 3, please replace with the following paragraph:

In another preferred embodiment, the light chain of the antibody binding an Hsp60-Epitope

has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: RASKSVSTSGYSYIH      (SEQ ID NO:7)

CDR2: LASNLES      (SEQ ID NO:8)

CDR3: QHSRELPLT      (SEQ ID NO:9)

The paragraph bridging pages 16 and 17, please replace with the following paragraph:

Furthermore, in another particularly preferred embodiment, the DNA sequence encoding the light chain of this antibody has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: A GGGCCAGCAA GAGTGTCACT ACATCTGGCT

          ATAGTTACAT ACAC      (SEQ ID NO:10)

CDR2: C TTGCATCCAA CCTAGAACATCT      (SEQ ID NO:11)

CDR3: CAGC ACAGTAGGGA GCTTCCGCTC ACG      (SEQ ID NO:12)

Paragraph 1, page 17, please replace with the following paragraph:

In another particularly preferred embodiment of the method of the invention, the heavy chain of the antibody binding a 26kDa-protein has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: GFTFNSTAMY      (SEQ ID NO:13)

CDR2: RIRSKSDNYATYYANSVKD      (SEQ ID NO:14)

CDR3: DHDKFPFYALDY      (SEQ ID NO:15)

Paragraph 2, page 17, please replace with the following paragraph:

In another particularly preferred embodiment, the DNA sequence encoding the heavy chain of the antibody binding the epitope of the 26kDa-protein has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: GG TTTCACCTTC AATTCTATG CCATGTAC  
          (SEQ ID NO:16)

CDR2: CGCATAAGAA GTAAAAGTGA TAATTATGCA ACATATTATG  
          CCAATTCAAGT GAAAGAC      (SEQ ID NO:17)

CDR3: GATCATG ATAAGTTCC TTTTACTAT GCTCTGGACT AC  
(SEQ ID NO:18)

Page 17, paragraph 3, please replace with the following paragraph:

In another particularly preferred embodiment of the method of the invention, an antibody, fragment or derivative thereof is used wherein the light chain of the antibody binding the 26kDa-protein has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: TASSSVSSSYLH (SEQ ID NO:19)  
CDR2: STSNLAS (SEQ ID NO:20)  
CDR3: HQYHRSPPT (SEQ ID NO:21)

The paragraph bridging pages 17 and 18, please replace with the following paragraph:

In addition, the DNA sequence encoding the light chain of the antibody has in another particularly preferred embodiment at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: A CTGCCAGCTC AAGTGTGAGT TCCAGTTACT TGCAC  
(SEQ ID NO:22)  
CDR2: AGCACTTCCA ACCTGGCTTC T (SEQ ID NO:23)  
CDR3: CAC CAGTATCATC GTTCCCCACC GACG (SEQ ID NO:24)

Page 18, paragraph 1, please replace with the following paragraph:

In another particularly preferred embodiment of the method of the invention, the heavy chain of the antibody binding an epitope of the  $\beta$ -urease has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: GFTFSSHFM (SEQ ID NO:25)  
CDR2: SISSGGDSFYPDSLKG (SEQ ID NO:26)  
CDR3: DYSWYALDY (SEQ ID NO:27)  
or  
CDR1: GYAFSTSWMN (SEQ ID NO:28)  
CDR2: RIYPGDGDTNYNGKFKG (SEQ ID NO:29)

CDR3: EDAYYSNPYSLDY (SEQ ID NO:30)

Page 18, paragraph 2, please replace with the following paragraph:

In another particularly preferred embodiment the DNA sequence encoding the heavy chain of the antibody binding an epitope of the  $\beta$ -urease has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: GG CTACGCATT AGTACCTCCT GGATGAAC  
(SEQ ID NO: 31)

CDR2: CGGATTATC CTGGAGATGG AGATACTAAC TACAATGGGA  
AGTTCAAGGG C (SEQ ID NO:32)

CDR3: GAG GATGCCTATT ATAGTAACCC CTATAGTTG GACTAC  
(SEQ ID NO:33)

or

CDR1: GG ATTCACTTC AGTAGGCCATT TCATGTCT  
(SEQ ID NO:34)

CDR2: TCCATTAGTA GTGGTGGTGA CAGTTCTAT CCAGACAGTC  
TGAAGGGC (SEQ ID NO:35)

CDR3: GACTAC TCTTGGTATG CTTTGGACTA C  
(SEQ ID NO:36)

The paragraph bridging pages 18 and 19, please replace with the following paragraph:

In another particularly preferred embodiment of the method of the invention, the light chain of the antibody binding an epitope of the  $\beta$ -urease has at least one of the following CDRs, preferably the CDR3 and still more preferably all of the three following CDRs:

CDR1: RASQSIGTRIH (SEQ ID NO:37)

CDR2: YGSEISIS (SEQ ID NO:38)

CDR3: QQSNTWPLT (SEQ ID NO:39)

or

CDR1: HASQNINVWLS (SEQ ID NO:40)

CDR2: KASNLHT (SEQ ID NO:41)

CDR3: QQGRSYPLT (SEQ ID NO:42)

Page 19, paragraph 1, please replace with the following paragraph:

Moreover, the DNA sequence encoding the light chain of this antibody preferably has the following CDRs:

CDR1: A GGGCCAGTCA GAGCATTGGC ACAAGAATAC AC  
(SEQ ID NO:43)

CDR2: TAT GGTTCTGAGT CTATCTCT (SEQ ID NO:44)

CDR3: CAACAG AGTAATACCT GGCGCTCAC G (SEQ ID NO:45)

or

CDR1: C ATGCCAGTCA GAACATTAAT GTTTGGTTAA GC  
(SEQ ID NO:46)

CDR2: AAG GCTTCCAAT TGCACACA (SEQ ID NO:47)

CDR3: CAACAG GGTCGAAGTT ATCCTCTCAC G (SEQ ID NO:48)

Page 22, paragraph 4, please replace with the following paragraph:

Furthermore, the invention relates to other antibodies, fragments or derivatives thereof, which specifically bind the epitope of the invention. These antibodies may, for example, be monoclonal antibodies which have been generated ~~according~~ according to standard methods using the epitope as hapten/component of an antigen.

Page 23, paragraph 5, please replace with the following paragraph:

The components of the diagnostic compound, compound, the test device of the invention and/or the kit of the invention may be packed in containers like vials or tubules, optionally in buffers and/or solutions. Possibly, one or several components may be packed in one container.